| Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer F De Bacco, P Luraghi, E Medico, G Reato, F Girolami, T Perera, ... JNCI: Journal of the National Cancer Institute 103 (8), 645-661, 2011 | 371 | 2011 |
| The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype F De Bacco, E Casanova, E Medico, S Pellegatta, F Orzan, R Albano, ... Cancer research 72 (17), 4537-4550, 2012 | 162 | 2012 |
| MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors P Luraghi, G Reato, E Cipriano, F Sassi, F Orzan, V Bigatto, F De Bacco, ... Cancer research 74 (6), 1857-1869, 2014 | 148 | 2014 |
| Poised transcription factories prime silent uPA gene prior to activation C Ferrai, SQ Xie, P Luraghi, D Munari, F Ramirez, MR Branco, A Pombo, ... PLoS biology 8 (1), e1000270, 2010 | 106 | 2010 |
| MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells F De Bacco, A D'Ambrosio, E Casanova, F Orzan, R Neggia, R Albano, ... EMBO molecular medicine 8 (5), 550-568, 2016 | 91 | 2016 |
| Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ... Cancer Discovery 12 (7), 1656-1675, 2022 | 56 | 2022 |
| Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype B Lupo, F Sassi, M Pinnelli, F Galimi, ER Zanella, V Vurchio, G Migliardi, ... Science translational medicine 12 (555), eaax8313, 2020 | 40 | 2020 |
| MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells C Boccaccio, P Luraghi, PM Comoglio Cancer research 74 (14), 3647-3651, 2014 | 38 | 2014 |
| A molecularly annotated model of patient-derived colon cancer stem–like cells to assess genetic and nongenetic mechanisms of resistance to anti-EGFR therapy P Luraghi, V Bigatto, E Cipriano, G Reato, F Orzan, F Sassi, F De Bacco, ... Clinical Cancer Research 24 (4), 807-820, 2018 | 30 | 2018 |
| Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity V Leuci, F Maione, R Rotolo, E Giraudo, F Sassi, G Migliardi, M Todorovic, ... Journal of Translational Medicine 14, 1-12, 2016 | 25 | 2016 |
| The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. S Lonardi, C Montagut, F Pietrantonio, E Elez, A Sartore-Bianchi, ... Journal of Clinical Oncology 38 (15_suppl), TPS4124-TPS4124, 2020 | 22 | 2020 |
| The MET oncogene as a therapeutical target in cancer invasive growth P Luraghi, F Schelter, A Krüger, C Boccaccio Frontiers in pharmacology 3, 164, 2012 | 21 | 2012 |
| A transcription-dependent micrococcal nuclease-resistant fragment of the urokinase-type plasminogen activator promoter interacts with the enhancer C Ferrai, D Munari, P Luraghi, L Pecciarini, MG Cangi, C Doglioni, F Blasi, ... Journal of biological chemistry 282 (17), 12537-12546, 2007 | 18 | 2007 |
| Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates M Li, P Luraghi, A Amour, XD Qian, PS Carter, CJ Clark, A Deakin, ... Analytical biochemistry 384 (1), 56-67, 2009 | 14 | 2009 |
| Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. S Siena, A Sartore-Bianchi, N Personeni, F Pietrantonio, G Germano, ... Journal of Clinical Oncology 37 (15_suppl), TPS2659-TPS2659, 2019 | 12 | 2019 |
| LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients S Lonardi, F Pietrantonio, NT Llavero, CM Viladot, AS Bianchi, ... Annals of Oncology 34, S1268-S1269, 2023 | 4 | 2023 |
| A transcription-dependent MNase-resistant fragment of the uPA promoter interacts with the enhancer C Ferrai, D Munari, P Luraghi, L Pecciarini, M Cangi, C Doglioni, F Blasi, ... J Biol Chem 282, 12537-12546, 2007 | 4 | 2007 |
| MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT … E Candiello, G Reato, F Verginelli, G Gambardella, A D′ Ambrosio, ... Molecular Oncology 17 (7), 1280-1301, 2023 | 1 | 2023 |
| miRNA-483-3p overexpression unleashes invasiveness of metastatic colorectal cancer by NDRG1 targeting and upregulation of the HER3-AKT axis E Candiello, G Reato, F Verginelli, A D'Ambrosio, G Gambardella, ... Cancer Research 81 (13_Supplement), 2358-2358, 2021 | 1 | 2021 |
| The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients S Lonardi, F Pietrantonio, NT Llavero, CM Viladot, AS Bianchi, ... ANNALS OF ONCOLOGY 34, S1268-S1269, 2023 | | 2023 |
